A unique event, during these exceptional times in which we are living. We’re talking about the 2020 Congress of the World Federation of Hemophilia which, from June 14 to 19, brought together in an exclusively virtual format the global network of healthcare providers, national hemophilia associations, people with hemophilia and other coagulation disorders, their families, and pharmaceutical companies.
Kedrion Biopharma was proud to support the “WFH Virtual Summit 2020” which, even though it is being held remotely, offered the greatest number of international experts an opportunity to discuss learn about the most current and relevant topics in the field of coagulation disorders, including access to care, a global and cross-sectional challenge made even more urgent by the COVID-19 pandemic.
“We believe that it was very important to organize this Virtual Summit” – explained Alain Weill, WFH President. “On one side, it is fundamental for us to maintain contact with the entire community worldwide and we know how essential it is for us and our partners, the pharmaceutical industry, scientists, researchers, healthcare providers, professionals, to meet and talk. On the other, in the Hemophilia world, we live in a very rapidly changing landscape: the environment is evolving technically, scientifically and we need to keep up-to-date with all the novelties. For the future, I think that we will have to adapt to social, developmental and environmental problems; a sort of new normal environment which will apply to everyone, including patients; challenges which may lead to more development and access to medicines.”
Kedrion, which has supported the participation of a large delegation of business partners in the Congress, participated with a virtual exhibit booth where “digital visitors” could find information about the company (including our newly published 2019 Annual Report) and the therapeutic solutions we offer in the field of coagulation disorders, as well as the many projects we are involved in around the world alongside the various associations for patients with Hemophilia.
Among the ongoing projects, we have initiated a home delivery program for Italian Hemophilia patients who, in recent months, have been staying at home as a means to reduce exposure to COVID-19, which can critically affect people at risk, including those who live with rare diseases.
The difficulties of these recent months have not prevented Kedrion from continuing to fulfill our mission. We have done everything possible to maintain the continuity of the company’s business and to protect patients, by ensuring the availability of the life-saving products they need. Now more than ever, we are proud to contribute to this goal, which is why, in Italy as in the rest of the world, we have strongly reaffirmed our commitment to the medical-scientific community and our support for local associations, by doing everything possible to keep alive the dialog, exchange, and trust built up over many years of working together.